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Abstract
MicroRNAs are endogenous short chain nucleotide RNAs that regulate gene function by
direct binding of target mRNAs. In this study, we investigated the effects of microRNA-206
(miR-206) on the development of gastric cancer. miR-206 was first confirmed to be down-
regulated in gastric cancer specimens. Conversely, upregulation of c-Met was confirmed in
tissue samples of human gastric cancer, with its level inversely correlated with miR-206
expression. Introduction of miR-206 inhibited cellular proliferation by inducing G1 cell cycle
arrest, as well as migration and invasion. Moreover, important proliferation and/or migra-
tion related molecules such as c-Met, CDK4, p-Rb, p-Akt and p-ERK were confirmed to be
downregulated by Western blot analysis. Targeting of c-Met also directly affected AGS cell
proliferation, migration and invasion. In vivo, miR-206 expressing tumor cells also dis-
played growth delay in comparison to unaffected tumor cells. Our results demonstrated
that miR-206 suppressed c-Met expression in gastric cancer and could function as a potent
tumor suppressor in c-Met overexpressing tumors. Inhibition of miR-206 function could
contribute to aberrant cell proliferation and migration, leading to gastric cancer
development.
Introduction
Gastric cancer is the fourth most common cancer and the second leading cause of cancer
related death in the world [1]. Its morbidity and mortality is particularly pronounced in Asian
countries due to a variety of influences [1]. Since its presentation is often associated with
advanced disease, there is an urgent need for advances in its detection and ultimately its man-
agement. At present, the understanding of microRNAs(miRNAs) on influencing gastric cancer
formation is occurring at a rapid pace.
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Since the first description of miRNA in the nematode C. elegans back in 1993, the impact of
these small non-coding RNAs has transcended multiple branches of molecular biology [2].
MiRNAs are highly tissue specific biomarkers with the potential to alter and transform resident
tissue. Because overexpression and under-expression have both been associated with tumori-
genesis [3], their roles as oncogenes and tumor suppressor genes are both well-established [4,
5]. Over the last several years, their impact on development and detection of solid organ
tumors including gastric cancer is slowly being elucidated. There are already several miRNAs
identified in the gastric cancer anti-apoptotic mechanism such as miR-21 and miR-148a [6, 7].
Other pathways influenced by miRNAs include cell cycle progression comprising of miR-222/
221, miR-106b/93/25 and miR-24 [6, 7].
One of the other promising new miRNAs for solid organ tumors includes miR-206 [8]. This
particular miRNA belongs to a group of “myomiRs” that is involved in skeletal muscle develop-
ment [9]. Having been associated with numerous other diseases including heart disease,
chronic obstructive pulmonary disease and Alzheimer’s, its role in oncogenesis received scru-
tiny more recently including rhabdomyosarcoma, lung cancer, colorectal cancer, schwannoma,
and gastric cancer [8, 9]. Although elevated in a few types of cancer including ovarian andWal-
denstrom macroglobulinemia, miR-206 is mostly suppressed in solid organ tumors [9]. miR-
206 has previously been shown to inhibit gastric cancer proliferation in part by suppressing
cyclin D2 [10]. In this investigation, we concentrated on the role of miR-206 in gastric cancer
oncogenesis through the c-Met pathway, which has traditionally been an influential signaling
pathway for oncogenesis in a variety of tumors [11]. c-Met has been predicted and shown to be
the target gene of multiple miRNAs including miR-206 [9, 12].
Results
Suppression of miR-206 led to increased c-Met expression in gastric
cancer
Real-time RT-PCR analysis was performed to detect the expression of miR-206 in 40 gastric
cancer specimens and normal tissues. miR-206 levels in most tissue samples of gastric tumor
(34/40) were found to be significantly lower than normal tissues (Fig 1A). miR-206 expression
was inversely related to the level of c-Met observed in tumor samples (Fig 1B). Most tumor
samples, with decreased miR-206 expression, showed high percentage (>50%) of c-Met stain-
ing. Conversely, tumors with normal expression of miR-206 showed very weak or negative c-
Met expression.
miR-206 induced G1 arrest and inhibited cell proliferation, migration and
invasion of AGS gastric cancer cells
As miR-206 expression was decreased in gastric cancer specimens, we sought to determine
whether the introduction of miR-206 had any biological effect on AGS cells. AGS cells trans-
fected with the miR-206 molecule showed inhibition of cell growth as compared to negative
control based on the MTS assay (Fig 2A). FACS analysis of the cells showed G1 cell cycle arrest
(S1 Fig). The number of colonies was also reduced with transfection of miR-206 (S2 Fig).
miR-206 can inhibit migration and invasion of AGS cells (Fig 2B and S3 Fig). A dramatic
reduction of migration towards the lower chambers was observed in miR-206 transfected AGS
cells (86 ± 15 vs. 165 ± 16 in AGS cells, P< 0.01, n = 3). In addition, cells transfected with
miR-206 showed that HGF-induced invasiveness was also significantly hampered following
miR-206 transfection (57 ± 12 vs. 116 ± 14 in AGS cells, P< 0.01, n = 3).
MiR-206 Inhibits Gastric Cancer via c-Met
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miR-206 downregulated c-Met expression and other cell cycle-related
proteins
We have previously identified c-Met as a direct target of miR-206 [9]. Western blot analysis
confirmed that c-Met expression was reduced by miR-206 transfection in AGS cells (Fig 3).
Concurrently, ectopic miR-206 also down-regulated the expression of CDK4, p-Rb, p-Akt and
p-ERK.
Downregulation of c-Met inhibited gastric cancer cell proliferation,
migration and invasion
Next, c-Met specific siRNA was first used to decrease the expression of c-Met in AGS cells (S4
Fig). MTS assays were performed to detect the proliferation of cells. AGS cells transfected with
Fig 1. miR-206 expression is associated with weak c-Met expression in gastric tumors. (A) Real-time
RT-PCR analysis showing the expression of miR-206 in normal tissues (set at 1) and the relative amount of
miR-206 in the tumors, as fold reduction. N: normal tissues; T: tumors. U6 snRNA was used as an internal
control. (B) miR-206 expression in cells was inversely correlated with c-Met. The representative
immunohistochemical staining of three gastric tumor specimens and their respective adjacent normal tissues
was presented. Sample numbers 2, 6, and 23 are identical with those in Real-time RT-PCR. Tumor cells
with > 50% positive staining were considered to have strong c-Met expression.
doi:10.1371/journal.pone.0128751.g001
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c-Met siRNA showed reduced cell growth as compared to negative control cells (Fig 4A;
25.10 ± 3.81% decrease). Both HGF-induced migration and invasion were decreased when
comparing c-Met siRNA transfected cells to negative control transfected cells. As indicated in
Fig 4B and S5 Fig, decrease in migration (88 ± 10 vs. 155 ± 15, P< 0.01, n = 3) and invasion
(72 ± 7 vs. 126 ± 12, P< 0.01, n = 3) were both statistically significant.
Introduction of miR-206 suppressed tumor growth in vivo
We next investigated if overexpression of miR-206 could repress tumor growth in vivo. After 8
weeks, the averaged tumor volumes were significantly lower from cells infected with lentivirus
expressing miR-206, as compared with control (Fig 5).
Discussion
Gastric cancer has remained a significant health care burden worldwide despite years of
research [1]. According to the WHO, gastric cancer remains one of the top cancer etiologies
with a high rate of mortality [1]. As with other solid organ tumors, it is increasingly clear that
better understanding of tumor oncogenesis is necessary to improve the prognosis of these
patients. Being prevalent in Asian countries, data are emerging on the role of miRNAs on the
development or suppression of gastric cancers [6].
miRNAs have dual functions in terms of gastric cancer development [6, 13]. Some miRNAs
are tumor suppressors and others are oncomiRs [6]. Ueda et al. found 22 miRNAs upregulated
and 13 downregulated in the plasma of patients with gastric cancer [13]. Targets that are under
investigation in the case of gastric cancer include regulators of p16, via miR-24, and p21
through miR-222/221 and miR-106b/93/25 [6]. Others, such as miR-21, can be upregulated in
up to 92% of gastric cancer tissue samples [14]. Candidates identified in gastric cancer serving
as tumor suppressors include miR-181b, miR-101 and miR-486 [6]. For instance, miR-101 is
thought to target EZH2, Cox-2, Mcl-1 and Fos [15]. miR-486 is thought to affect OLFM4, pos-
sibly affecting apoptosis downstream [16].
Having established that the majority of miRNAs serve as tumor suppressors, we investigated
the c-Met pathway in gastric cancer. In studying the c-Met pathway for rhadbomyosarcoma,
we found the importance of this pathway in sarcoma [9]. c-Met is known to be dysregulated in
gastric cancer [11, 17–19]. The MET proto-oncogene encodes a protein known as hepatocyte
growth factor (HGF) receptor which possesses tyrosine kinase activity [18]. We normally find
it expressed only in stem cells but have also seen its dysregulation in oncogenesis [18]. In this
Fig 2. Ectopic miR-206 induces G1 arrest and inhibits cell proliferation, migration and invasion. (A)
MTS cell proliferation assay was carried out on day 3 as indicated. (B) AGS cells were assessed with
Transwell and Matrigel assays. The number of cells that had migrated through the culture insert pores (left) or
had invaded through the Matrigel insert pores (right) was quantified by counting five independent visual fields.
*: Differences in cell migration or invasion between miR-206 and negative control transfected cells were
significant, P < 0.01.
doi:10.1371/journal.pone.0128751.g002
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study, we were able to confirm that c-Met is significantly involved in gastric cancer and its role
as a miR-206 target is pivotal in oncogenesis.
Cell cycle progression is dysregulated in gastric cancer. Based on previous reports, cyclin D2
is elevated in gastric cancer when miR-206 is affected [10]. miR-206 has been shown to be a
potent prognostic marker [10]. Its downregulation is associated with shorter overall survival.
Restoration of miR-206 leads to G0/G1 cell cycle arrest, confirming its role as a tumor suppres-
sor. Our work also showed cell cycle dysregulation with CDK4 and phosphorylated-Rb being
affected. CDK4 is a member of the cycline dependent kinase family with ser/thr protein kinase
activity. It leads to G1 phase progression. In addition, the kinase leads to the phosphorylation
of Rb, which is a tumor suppressor involved in cell cycle progression.
Fig 3. miR-206 downregulates the expression of c-Met, cycle-related proteins CDK4, and
phosphorylated-Rb (p-Rb) in AGS cells.miR-206 also downregulates expression of p-Akt and p-ERK1/2,
but not total Akt or ERK1/2.
doi:10.1371/journal.pone.0128751.g003
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PLOS ONE | DOI:10.1371/journal.pone.0128751 July 17, 2015 5 / 11
Although similar findings have been confirmed in gastric, ovarian and breast cancers, the
role of miR-206 seems to have an opposite effect in colon cancer [6, 20]. An inverse correlation
was noted between miR-206 and KLF4 in a panel of human colon cancers [20]. KLF4, which
has oncogenic properties in other cancers such as breast, skin and lung, functions as a tumor
suppressor in colon cancer [20]. Its promoter is hyper-methylated with elevated levels of miR-
206 leading to downregulation of KLF4 [20]. These findings indicate that miR-206 may not
function similarly in all epithelial cells, which negates the one size fits all approach in
chemotherapeutics.
In the present study, we identified a mechanism for regulation of c-Met gene expression
through miR-206 in gastric cancer. c-Met overexpression following miR-206 downregulation
seems to be the common etiology for the pathogenesis of gastric cancer in the majority of sam-
ples examined in this study. In summary, we demonstrated that miR-206 negatively modulates
the c-Met signaling pathway involved in cell proliferation and migration. Our studies will
hopefully have important clinical consequences in the treatment of gastric cancer. miR-206 is a
candidate for both immunohistochemical detection of small tumors and possible target for bio-
logical therapeutics.
Fig 4. Downregulation of c-Met inhibits AGS cell proliferation, migration and invasion. (A) MTS cell
proliferation assay was carried out on day 3 after transfection. (B) The impact of c-Met siRNA on AGS cells
was quantified using culture or Matrigel inserts.
doi:10.1371/journal.pone.0128751.g004
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Materials and Methods
Cell culture
The human gastric cancer cell line, AGS, purchased from ATCC (Manassas, VA), was grown
in Ham's F-12 Medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum
(FBS; Hyclone, Logan, UT).
Ethics statement
This study was carried out in strict accordance with the recommendations and approval of the
Wenzhou Medical University Animal Care and Use Committee (Permit Number:
WZMCOPT-043011). Forty gastric tumor specimens and normal donor gastric tissues were
obtained from the second affiliated hospital of Wenzhou Medical University (Wenzhou,
China). Sample collection was approved by the Wenzhou Medical University Ethics Commit-
tee on research involving human subjects, and written informed consent was obtained from
each case. All experiments were performed in compliance with the Helsinki Declaration and
national laws.
Fig 5. Introduction of miR-206 in AGS cells suppresses tumor growth in nudemice. (A) Representative
photographs of nude mice 8 weeks after inoculation. (B) Average volume of tumors was statistically
significant. *: n = 5 each, P < 0.01.
doi:10.1371/journal.pone.0128751.g005
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Quantitative RT-PCR
Total RNA was extracted from human gastric tumor samples and normal controls with Trizol
reagent (Invitrogen). 10 ng of total RNA were used for cDNA synthesis by the Taqman Micro-
RNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA), and miR-206 expres-
sion level was quantified by the Taqman MicroRNA Assay (Applied Biosystems). Real-time
RT-PCR was performed using the Applied Biosystems ViiA 7 Real-Time PCR System (Applied
Biosystems).
Immunohistochemical staining of c-Met
Sections of formalin-fixed paraffin-embedded human gastric tumor specimens (5 μm) were
made and then de-paraffinized with xylene and ethanol. Slides were treated with 0.3% hydro-
gen peroxide and then incubated overnight at 4°C with c-Met antibody at 1:300 dilution (CST,
Beverly, MA). Immunohistochemical staining was performed using the EnVision HRP/DAB
detection system (Dako, Glostrup, Denmark).
Cell proliferation assay
AGS cells were plated at 2000 cells per well in 96-well plates (Costar, High Wycombe, UK) for
each transfection. Transfections were performed with reagent (Lipofectamine RNAiMAX;
Invitrogen), in triplicates. For each well, 50 nMmiR-206 mimics molecule (Ambion, Austin,
TX), or a negative control (Ambion) transfection was employed. After 72 hours of culture, cell
proliferation was assessed by MTS assay (CellTiter 96 AQueous; Promega, Madison, WI).
Transwell migration assays
24 hours following transfection, AGS cells were harvested by trypsinization and washed once
with D-Hanks solution (Invitrogen). To measure cell migration or invasion, 8-μm pore size
culture or Matrigel inserts (Transwell; Costar) were placed into the wells of 24-well culture
plates. In the lower chamber, 400 μL F-12 containing 10% FBS and 20 ng/ml of HGF was
added. Then, 5x104 cells were added to the upper chamber. After 20 hours of incubation, the
cells that had migrated through the pores were stained with crystal violet and observed under
the microscope (Zeiss, Oberkochen, Germany) using a 20X objective.
Western blot analysis
AGS cells (1x105) were seeded in 6-well plates and grown in F-12 for 24 hours prior to transfec-
tion. 72 hours after transfection, the cells were washed with cold PBS and subjected to a lysis
buffer (35 mM Tris-Cl [pH 6.8], 20 g/L sodium dodecyl sulfate [SDS], 100 mM dithiothreitol).
Protein lysates (20 μg each) were separated using 8% SDS-polyacrylamide gel electrophoresis,
then electro-transferred onto nitrocellulose filter membranes. The membranes were blocked
with a buffer containing 5% nonfat milk in PBS with 0.05% Tween-20 for 2 hours and incu-
bated overnight with antibody at 4°C. After a second wash with PBS containing 0.05% Tween-
20, the membranes were incubated with peroxidase-conjugated secondary antibodies (Milli-
pore, Darmstadt, Germany) and developed with an enhanced chemiluminescence detection kit
(Pierce, Rockford, IL). GAPDH was used as a loading control. Antibodies for CDK4, p-Rb,
ERK, Akt, p-ERK, p-Akt, c-Met and GAPDH were from Cell Signaling Technology (Beverly,
MA).
MiR-206 Inhibits Gastric Cancer via c-Met
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SiRNA assays
c-Met-specific siRNA (Ambion) and negative control siRNA (Ambion) were used to downre-
gulate c-Met expression in AGS cells. 50 nM of c-Met-specific siRNA or negative control
siRNA was transfected into AGS cells with Lipofectamine RNAiMAX. MTS assay was carried
out 72 hours after transfection, whereas Transwell and Matrigel assays were performed 24
hours after transfection, as described above.
In vivo tumor growth assay
The pre-microRNA expression constructs lenti-miR-206 and pCDH-CMV-MCS-EF1-copGFP
control vector were purchased from System Biosciences (Mountain View, CA). AGS cells were
infected with lentivirus expressing miR-206 or negative control. Female nude mice, 6 weeks of
age, were inoculated with AGS cells (8x106) expressing miR-206 or negative controls in their
flanks, and then sacrificed after 8 weeks. Tumor size was measured and volume was calculated
using the formula: (L xW2) x 0.5, (L, length;W, width), according to the method previously
reported [21]. All studies and procedures were approved by the Wenzhou Medical University
Animal Care and Use Committee.
Statistical analysis
All data were shown as the mean ± SEM. Results shown are expressed as the mean
value ± SEM of the results obtained from triplicates in one experiment. Results represent those
obtained in three separate experiments. Differences between experimental groups and control
groups were analyzed using the Student’s t-test. Statistical significance was accepted at
P< 0.05.
Supporting Information
S1 Fig. FACS analysis of AGS cells transfected with miR-206. AGS cells were collected 48
hours after transfection with miR-206 or NC, stained with propidium iodide, and analyzed by
flow cytometry. Ten thousand cells were evaluated in each sample. The most representative
results in three independent experiments are depicted.
(TIF)
S2 Fig. Colony formation assay. AGS cells transfected with miR-206 or NC were seeded at
low density. After 7 days, colony formation was determined by staining with crystal violet. Typ-
ical results in three independent experiments are shown.
(TIF)
S3 Fig. The effects of miR-206 on AGS cells were assessed with Transwell and Matrigel
assays. The number of cells that had migrated through the culture insert pores (up) or had
invaded through the Matrigel insert pores (down) was photographed using a 20X microscope
objective.
(TIF)
S4 Fig. Downregulation of c-Met by siRNA.Western blot analysis was performed to confirm
suppression of c-Met expression after lipofectamine transfection of AGS cells with either c-Met
siRNA or a negative control (NC).
(TIF)
S5 Fig. The effects of c-Met siRNA on AGS cells were assessed with Transwell and Matrigel
assays. The number of cells that had migrated through the culture insert pores (up) or had
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